Cargando…
Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes
Imeglimin is a novel agent currently in development to treat type 2 diabetes. Laboratory studies have demonstrated that it has the potential to impact the three main pathophysiologic components of type 2 diabetes: impaired glucose uptake by muscle tissue, excess hepatic gluconeogenesis, and increase...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561051/ https://www.ncbi.nlm.nih.gov/pubmed/26254210 http://dx.doi.org/10.1007/s40268-015-0099-3 |